Publications & Presentations
Publication Highlights
Value
- Key Economic & Value Considerations in the US Market for PPTs
- Key Economic & Value Considerations for PDMPs in Europe
- Immunoglobulin Replacement Therapy Cost-Effectiveness Study
- The Impact of Plasma-Derived Therapies in Europe: The Health and Economic Case for Ensuring Sustainable Supply
- Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
- Plasmavigilance-Adverse events among US Source plasma donors
- Plasma Collections and Immunoglobulin Manufacturing in the Era of COVID-19
- Industry call for COVID-19 convalescent plasma collections
- Frequent source plasma donors are not at risk of iron depletion: the Ferritin Levels in Plasma Donor (FLIPD) study
- Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years experience of the plasma protein manufacturers
- Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies
- Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies.
- Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies
Presentation Highlights
- "The revision of the EU Blood Directive: How to enhance plasma collection by getting more donors via increased regulatory efficiency?”
- Plasma Saves Lives: Addressing the COVID-19 Pandemic
- PlasmaVigilance: Source Plasma Donor Hemovigilance Activities and Results
- Europe's Need for More Plasma – Event Report
- Ensuring Appropriate Patient Access to Plasma Derived Medicinal Products – Event Report
- PPTA 2020 Annual Report